Singulex: Next-Gen Immunodiagnostics

Singulex originally developed its Single Molecule Counting technology for research applications, but it is poised to launch a clinical diagnostics tool that incorporates the highly sensitive technology.

Singulex Inc., the privately held immunodiagnostics company based in Alameda, CA, is close to market launch of its Clarity in vitro diagnostic system. The fully automated platform is designed to bring the benefits of the company’s Single Molecule Counting (SMC) technology to hospital and reference laboratories.

Singulex bills its SMC technology as “the backbone of next generation immunodiagnostics, because it offers “unprecedented sensitivity and dynamic range...

More from Innovation

More from In Vivo